This is the first study to discuss refining the HER2‐low‐positive BC focusing upon the distinction between IHC score 1+ IHC score 0 to provide a more reproducible and non‐arbitrary scoring criteria compared with the current definition, which is more subjective. Here, ERBB2 is linked to breast cancer.